Drugs giant Roche said it would invest $50 billion in the U.S. over the next five years as they grapple with Donald Trump’s ...

Roche posted higher sales that beat analysts’ expectations on higher demand for its key drugs.

Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo ...

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

The pharma giant said the investment would create more than 12,000 jobs, as it joins rival Novartis in expanding its ...

Roche on Tuesday said it will invest $50 billion in the United States over the next five years, in one of the biggest inward ...

HEMLIBRA has strong market potential due to its unique, subcutaneous prophylactic treatment for Hemophilia A, including patients with and without factor VIII inhibitors. With increasing global ...

Developed by Chugai Pharmaceutical Co., Ltd., HEMLIBRA is co-developed internationally by Chugai, Roche, and Genentech. In ...

Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of ...

Winners of the ADGHW Innovation Awards 2025 addressed prenatal gene editing, robotic organ transplantation, precision drug delivery, and novel pain ...

an astrobiologist at RISE Research Institutes of Sweden who also works on the Mars Perseverance science team. “Because one important question is if there was life, when was the delta active and ...

This is an extraordinary technological leap in genetic engineering efforts for both science and for conservation as well as preservation of life, and a wonderful example of the power of ...